CJC-1295 (No DAC) 5mg + Ipamorelin 5mg – Research Peptide Blend (Research Use Only)
CJC-1295 (No DAC) and Ipamorelin are synthetic peptides investigated in the fields of endocrinology, growth-hormone signaling, metabolic physiology, and peptide pharmacology. This fixed 1:1 research blend contains 5 mg of CJC-1295 (No DAC) and 5 mg of Ipamorelin, supplied as a homogeneous lyophilized powder for controlled laboratory research.
The combination provides an experimental model for investigating the interaction between growth hormone–releasing hormone (GHRH) signaling and growth hormone secretagogue receptor (GHS-R) signaling. Rather than describing the combination as therapeutically “synergistic,” it is more scientifically accurate to characterize it as a model for studying complementary pathways involved in the regulation of endogenous growth hormone secretion.
This product is intended exclusively for laboratory, scientific, and preclinical research. It is not approved as a drug and is not intended for human or veterinary use.
Mechanistic Profile
• CJC-1295 (No DAC) is investigated as a synthetic analog of growth hormone–releasing hormone (GHRH)
• Ipamorelin is investigated as a selective growth hormone secretagogue receptor (GHS-R) agonist
• Provides a model for studying interaction between GHRH and GHS-R signaling pathways
• Enables investigation of pituitary growth-hormone secretion mechanisms
• Supports research into downstream GH/IGF-1 axis signaling
• Provides a model system for studying endocrine feedback and pulsatile hormone secretion
Research Significance
In experimental settings, the combination is primarily investigated for:
✅ studying regulation of the somatotropic or GH axis
✅ analyzing interactions between GHRH and ghrelin-receptor signaling
✅ investigating pituitary mechanisms involved in growth hormone secretion
✅ examining downstream GH and IGF-1 signaling pathways
✅ studying endocrine feedback mechanisms and hormone pulsatility
✅ evaluating peptide pharmacodynamics and receptor-mediated signaling
These applications are intended exclusively for basic, analytical, and preclinical research.
⚙️ How the Combination Works Under Experimental Conditions
CJC-1295 (No DAC) is designed to model aspects of endogenous GHRH signaling. Activation of the GHRH receptor pathway can promote signaling within somatotroph cells of the anterior pituitary and contribute to growth-hormone release.
Ipamorelin acts through the growth hormone secretagogue receptor (GHS-R), providing a separate signaling pathway involved in GH secretion.
Studying these two pathways together allows researchers to examine how simultaneous activation of complementary receptor systems influences pituitary GH secretion, hormone pulsatility, and downstream endocrine signaling.
Research-Observed Parameters
Experimental research may evaluate:
• Growth hormone concentration and secretion patterns
• IGF-1 concentrations and downstream signaling
• GHRH-receptor and GHS-R pathway activity
• Pituitary somatotroph response
• Endocrine feedback mechanisms
• Pharmacokinetic and pharmacodynamic characteristics
• Receptor signaling and peptide stability
Importantly, experimental observations should not automatically be interpreted as evidence of improved muscle growth, fat loss, tissue regeneration, anti-aging effects, or therapeutic benefit in humans.
Lyophilized Formulation
The peptides are supplied in lyophilized (freeze-dried) form, a commonly used format for laboratory peptide storage. Lyophilization removes water under controlled conditions and can help maintain peptide integrity during storage when appropriate conditions are maintained.
Following reconstitution, peptide stability depends on factors including solvent composition, pH, temperature, concentration, container compatibility, sterility, and storage conditions. Appropriate formulation and stability testing should therefore be performed according to the requirements of the specific research protocol.
Scientific Context
The combined investigation of GHRH analogs and growth-hormone secretagogues is well established within neuroendocrine research. Research into these pathways has contributed to the understanding of pituitary GH regulation, receptor signaling, hormone pulsatility, and the broader somatotropic axis.
For scientific literature searches, relevant terminology includes:
• “CJC-1295 GHRH analog”
• “Ipamorelin GHS-R agonist”
• “GHRH growth hormone secretagogue interaction”
• “growth hormone secretagogue receptor signaling”
• “somatotropic axis peptide pharmacology”
Product Specification
Composition:
• CJC-1295 (No DAC): 5 mg
• Ipamorelin: 5 mg
• Total peptide content: 10 mg
• Ratio: 1:1
• Form: Lyophilized powder
• Intended application: Laboratory and scientific research
Safety & Regulatory Notice
• Research Use Only (RUO)
• Not approved as a pharmaceutical drug
• Not intended for human or veterinary use
• Not intended for self-administration
• Not intended to diagnose, treat, cure, or prevent any disease
• Laboratory handling should follow appropriate institutional safety and regulatory procedures
• Research findings should not be represented as established clinical efficacy
⚠️ FOR RESEARCH USE ONLY — NOT FOR HUMAN OR VETERINARY USE.
